Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer
Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions
PD‑L1 expression and microsatellite instability (MSI) in cancer of unknown primary site
Precision medicine for urothelial carcinoma: An international perspective
Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study
The LACOG-0415 phase II trial: abirateroneacetate and ADT versus apalutamide versusabiraterone acetate and apalutamide inpatients with advanced prostate cancerwith non-castration testosterone levels
Watch and wait policy remainsexperimental for the management ofrectal cancer
Phase III, Randomized, Double-Blind, Multicenter TrialComparing Orteronel (TAK-700) Plus Prednisone WithPlacebo Plus Prednisone in Patients With MetastaticCastration-Resistant Prostate Cancer That Has ProgressedDuring or After Docetaxel-Based Therapy: ELM-PC 5
What are the personal and professional characteristics that distinguishthe researchers who publish in high- and low-impact journals?A multi-national web-based survey
Metformin plus lrinotecan in patients with refractorycolorectal cancer: a phase 2 clinical trial
